Cover Image
市場調查報告書

肺發炎的開發中產品分析

Pulmonary Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 303577
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
肺發炎的開發中產品分析 Pulmonary Inflammation - Pipeline Review, H1 2014
出版日期: 2014年05月21日 內容資訊: 英文 54 Pages
簡介

肺發炎是指肺臟內部發生膧脹的疾病。主要症狀有呼吸困難及咳嗽、運動耐力低落等。肺部發炎主要致病要因有其他肺病的感染病史(肺炎、結核等)、胸部外傷、藥劑抗性、其他疾病(紅斑性狼瘡(狼瘡)、類風濕性關節炎、癌症、肝臟病、肺栓塞症及其他)等。

本報告提供全球各國的肺發炎的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

肺發炎概要

治療藥的開發

  • 肺發炎開發中產品:概要
  • 肺發炎開發中產品:比較分析

各企業開發中的肺發炎治療藥

大學/研究機關研究中的肺發炎治療藥

開發中的產品概要

  • 臨床實驗階段的產品
  • 初期階段的產品

肺發炎治療藥:開發中的產品一覽(各企業)

肺發炎治療藥:研究中的產品一覽(大學/研究機關別)

肺發炎治療藥的開發企業

  • Idera Pharmaceuticals, Inc.
  • Pharmaxis Limited
  • InDex Pharmaceuticals AB
  • Resolvyx Pharmaceuticals, Inc.
  • Asmacure Ltee
  • Celtaxsys, Inc.

肺發炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 分子類別

藥物簡介

  • CTX-4430
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • IMO-3100
  • DIMS-9054
  • RX-20001
  • P-7
  • PXS-4728-A
  • P-16
  • 放射線性肺炎·放射線誘發性肺損傷的治療藥
  • CpGoligo核苷酸
  • ASM-002
  • ASM-003
  • ASM-004
  • ASM-005
  • PXS-4681-A

肺發炎治療藥:開發中產品的最新趨勢

肺發炎治療藥:暫停開發的產品

附錄

圖表一覽

目錄
Product Code: GMDHC4953IDB

Global Markets Direct's, 'Pulmonary Inflammation - Pipeline Review, H1 2014', provides an overview of the Pulmonary Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Pulmonary Inflammation - Overview
    • Pipeline Products for Pulmonary Inflammation - Comparative Analysis
  • Pulmonary Inflammation - Therapeutics under Development by Companies
  • Pulmonary Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Inflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Pulmonary Inflammation - Products under Development by Companies
  • Pulmonary Inflammation - Products under Investigation by Universities/Institutes
  • Pulmonary Inflammation - Companies Involved in Therapeutics Development
    • Idera Pharmaceuticals, Inc.
    • Pharmaxis Limited
    • InDex Pharmaceuticals AB
    • Resolvyx Pharmaceuticals, Inc
    • Asmacure Ltee
    • Celtaxsys, Inc.
  • Pulmonary Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CTX-4430 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-3100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DIMS-9054 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-20001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-7 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-4728-A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-16 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Radiation Pneumonitis and Radiation Induced Lung Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CpG Oligonucleotides - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASM-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASM-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASM-004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASM-005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-4681-A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Second Generation LTA4H Inhibitor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pulmonary Inflammation - Recent Pipeline Updates
  • Pulmonary Inflammation - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Inflammation, H1 2014
  • Number of Products under Development for Pulmonary Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Pulmonary Inflammation - Pipeline by Idera Pharmaceuticals, Inc., H1 2014
  • Pulmonary Inflammation - Pipeline by Pharmaxis Limited, H1 2014
  • Pulmonary Inflammation - Pipeline by InDex Pharmaceuticals AB, H1 2014
  • Pulmonary Inflammation - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2014
  • Pulmonary Inflammation - Pipeline by Asmacure Ltee, H1 2014
  • Pulmonary Inflammation - Pipeline by Celtaxsys, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Pulmonary Inflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Pulmonary Inflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Pulmonary Inflammation, H1 2014
  • Number of Products under Development for Pulmonary Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top